Moderna says patent ruling not to affect COVID-19 vaccine development
Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma.
Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma.
An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna`s arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.
See Zee Business Live TV streaming below:
Moderna said the court`s ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.
Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
8th Pay Commission: If implemented, how much salary hike is expected? Check latest update on pay matrix of central employees
Met Gala 2024: When and how to watch Met Gala red carpet livestream in India - Check date, time, venue, theme, guest list and other details
02:47 PM IST